B: 25-28 Flashcards
Synthetic opiates
- Fentanyl- (strong.) analgeisa and anesthetica
- Merperidine- strong. analgesia , causes tachycardia bcz similar to atropine
-
Methadone (strong agonist): management of opoid withdrawal syndrome , maintenance program for addicts
- Potent mui-receptor agonist
- Potent NMDA antagonist
- NE, SE reuptake inhibitor
-
Tramadol- (weak.) analgesia. also
- inhibits 5HT, NE reuptake (serotonin syndrome)
- analgesic use
-
Loperamide, Diphenoxylate- (weak agonist) anti diarrhea
- loperamide has no cns effect
- Dextromethorphan (weak synthetic agonist) - analgesic, anti-tussive, inhibit 5HT, NE reuptake
Opioid receptrors are coupled to
Gi protein
Opioid
- Miu-
- presynaptic
- postsynaptic
- increace K conductance. > IPSP
- Endrophines>Enkephalin> dynorphin
- Sedation, decrease respiration, decreased GI motility, analgesia
- Delta-
- presynaptic
- enkephalin> endorphine> dynorphin
- analgesia
- Kappa-
- presynaptic
- dynorphin>> endorphins, enkephalin
- analgesia, psichomimetic, GI motility decrease
- All modulate hormone and NT release
ALL are Gi coupled - ALL are Presynaptic
- reduce Ca influx.
- decrease transmitter release
- increase K conductance
Opiates antagonists
-
Naloxone: strong antagonist of all opioid R
- Semi-synthetic
- used in case of opioid overdose ( IV )
- T1/2= 1-2 hrs
- stronger affinity for opioid R ; kicks opioid out!
-
methyl-Naltrexone( strong antagonist)
- synthetic
- management of opioid withdrawal syndrome (oral )
- management of alcohol withdrawal syndrome
- T1/2= up to 48 hrs
No relax zone
Natural opioids
Morphine- (strong agonist) Analgestic, anasthesia, acute pulm. edema
Codeine- (weak agonist) metabolised in the liver (CYP450) to produce morphine which is ten times more potent against the mu receptor.
Binding of codeine or morphine to the mu opioid receptor results in hyperpolarization of the neuron leading to the inhibition of release of nociceptive neurotransmitters causing an
analgesic effect and increased pain tolerance due to reduced neuronal excitability
Anti-tussive
Modulate transmission in many sites in the brain and spinal cord
endogenous Opioid peptides
Endorphine (u)
Enkephalin (Delta)
Dynorphine (Kappa)
Which are the semi synthetics opioids
Hydromorphone( strong agonist) - Analgesic use
Oxycodone (strong agonist)- Analgesic use
Dihydrocodeine (weak agonist)- Antitussive, analgesic
Buprenophine (Mixed activity : Partial u-agonist, Kappa-antagonist, deltaa-antagonist), maintenance programs for addicts, managing opioid withdrawal syndrome,
Nalbuphine (mixed activity) for spinal anasthesia
HOD -BN (hood black ni**a)
Teratogenicity of opoids
- Respiratory depression
- pre-eclampsia (pregnancy HTN +proteinurea)
- fetal death
- physical dependence –> Neonatal abstinence syndrome(NAS) = conditions caused when a baby withdraws from certain drugs he’s exposed to in the womb before birth. NAS is most often caused when a woman takes drugs called opioids during pregnancy
Acute toxicity opioids symtpoms and managements
- pupillary constriction “pin point pupil”
- respiratory paralysis
- coma
- IV naloxone
- supportive
Dependence of opoid symptoms and management
- yawning
- increased secretions: lacrimation, rhinorhhea, salivation
- anxiety, sweating, hyperthermia
- muscle cramps, spasm , CNS-originating pain
- piloerection
- methadone, buprenorphine, naltrexone
- clonidine: decreases sympathetic symptoms ( sweating, hot flashes, watery eyes, and restlessness.)
- supportive
NSAID’s general drugs
-
Aspirin- irreversible COX inhibition (acetylation of serine OH group)
- oral
- Low dose: first order kinetics (T1/2= 3-5 hrs)
- High dose: zero order elimination (T1/2= 15 hrs)
- renal elimination
- Allopurinol- Inhibits Xantine Oxidase–>decreased purine metab.–>decreased uric acid
- Rasburicase- It is an Urate oxidase enzyme that metabolize uric acid into Allantoin
-
Colchicine- inhibits Microtubule assembly
- binds tubulin > altered microtubular polymerization
- decreased LTB4 > altered leukocyte and granulocyte migration
- oral, parenteral
Aspirin- indications
- Low dose (<300mg/dl)
- Anti-platelet aggregation :
- Post MI prophylaxis
- reduce risk of CV events
- Anti-platelet aggregation :
- Medium dose (300-2400 mg/dl)
- analgesic
- antipyretic
- High dose (2400-5000 mg/dl)
- Anti-inflammatory effect
aspirin SE
- GI irritation ( PUD, gastritis, GI bleeding)
- Renal damage ( AKI, interstitial nephritis)
- tinnitus, vertigo, hearing loss
- Increased bleeding time
- chondrotoxic
- Uric acid
- high dose: uricosuria
- low dose: hyperuricemia
- NSAID induced asthma ( due to high LT)
- hypersensitivity rxn ( due to high LT)
- Hyperventilation ( respiratory alkalosis) early
- metabolic acidosis, high anion gap (late)
- dehydration, hyperthermia
- collapse, coma , death
- labor prolongation
- rey’s syndrome in children treated with aspirin for viral infection –>
- acute liver failure,
- encephalopathy
Colchicine indication, administration
- oral, parenteral
- acute gout - high doses (use is limited due to severe diarrhea)
- chronic gout - low doses
- familial mediterranian fever
- potential role in management of pericardial disease (pericarditis, pericardial effusion)
SE Colchicine
administration
- Microtubule assembly inhibitor
- oral, parenteral
- acute:
- severe diarrhea,
- GI pain
- chronic:
- hematuria
- alopecia
- myelosuppression
- gastritis
- peripheral neuropathy